Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17805439 | 0.88 | ADORA3 (0.42) | MAPK1RORCCARM1PRMT6PRMT5 | |
| SCHEMBL31054247 | 0.85 | EPHX2 (0.53) | MAPTMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL236978 | 0.84 | CARM1 (0.52) | MAPK1CARM1PRMT6LMNAALDH1A1 | |
| SCHEMBL3696096 | 0.84 | CARM1 (0.52) | MAPK1CARM1PRMT6LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1170216 | 0.81 | CARM1 (0.50) | MAPK1CARM1PRMT6LMNAALDH1A1 | |
| SCHEMBL1068979 | 0.79 | CARM1 (0.49) | MAPK1CARM1PRMT6LMNAALDH1A1 | |
| SCHEMBL1425186 | 0.79 | KDM4E (0.52) | MAPK1CARM1PRMT6LMNAALDH1A1 | |
| SCHEMBL23247149 | 0.79 | PLK4 (0.54) | MAPK1RORCLMNALRRK2MAPT | |
| SCHEMBL488077 | 0.79 | MAPK1 (0.44) | MAPK1LMNAPLK4 | |
| SCHEMBL178453 | 0.79 | MAPK1 (0.53) | MAPK1RORCLMNALRRK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375895-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010068564-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. (US) | 2010-06-17 | — | — | WO | claimed |
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2020200284-A1 | PREPARATION METHOD FOR TRICYCLIC COMPOUND AND USE OF SAME IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-10-08 | — | — | WO | disclosed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9266876-B2 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | MAPK1 3382/4885RORC 905/4885CARM1 157/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | MAPK1 1099/4885RORC 2998/4885CARM1 2603/4885 |
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | CXCR3, CXCR1, CXCR2 | MAPK1 3385/4885RORC 112/4885CARM1 1791/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | MAPK1 1093/4885RORC 2885/4885CARM1 2534/4885 |
| US-12122750-B2 | AT2R antagonists and uses thereof | AGTR2, AGTR1, AVPR2 | MAPK1 1099/4885RORC 2998/4885CARM1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.